Ionis Pharmaceuticals (IONS) Stock Surges on Promising Hepatitis B Drug Trial Results

IONS stock advanced after partner GSK released positive Phase 3 data for bepirovirsen, showing 19% functional cure rates during FDA priority review period.

The post Ionis Pharmaceuticals (IONS) Stock Surges on Promising Hepatitis B Drug Trial Results appeared first on Blockonomi.